Next Article in Journal
Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis
Next Article in Special Issue
Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma
Previous Article in Journal
Distinct Molecular Pattern-Induced Calcium Signatures Lead to Different Downstream Transcriptional Regulations via AtSR1/CAMTA3
Previous Article in Special Issue
Chronic HCV Infection Is Associated with Overexpression of Human Endogenous Retroviruses that Persists after Drug-Induced Viral Clearance
 
 
Review

Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma

1
Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, Korea
2
Department of Radiology, Soonchunhyang University College of Medicine, Seoul 04401, Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(21), 8165; https://doi.org/10.3390/ijms21218165
Received: 21 September 2020 / Revised: 28 October 2020 / Accepted: 28 October 2020 / Published: 31 October 2020
(This article belongs to the Special Issue Molecular Pathogenesis of Viral Hepatitis and Liver Cancer)
Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE. View Full-Text
Keywords: transarterial chemoembolization; hepatocellular carcinoma; refractoriness; combination therapy transarterial chemoembolization; hepatocellular carcinoma; refractoriness; combination therapy
MDPI and ACS Style

Chang, Y.; Jeong, S.W.; Young Jang, J.; Jae Kim, Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2020, 21, 8165. https://doi.org/10.3390/ijms21218165

AMA Style

Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2020; 21(21):8165. https://doi.org/10.3390/ijms21218165

Chicago/Turabian Style

Chang, Young, Soung Won Jeong, Jae Young Jang, and Yong Jae Kim. 2020. "Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma" International Journal of Molecular Sciences 21, no. 21: 8165. https://doi.org/10.3390/ijms21218165

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop